The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small cell lung cancer (NSCLC). In this interview, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses the aims and design of the study, in addition to an exciting data update pre-ASCO. Prof. Heck highlights the broad spectrum of this study, meaning that patients with different types of mutations, including EGFR and ALK, were eligible. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
